IP Library › Granted Patent US 12,349,706
Granted Patent B2
US 12,349,706 · App. 17/392,247 · Granted Jul 8, 2025

Compositions and methods related to excipients and cannabinoid formulations

Inventors: C. Russell Thomas (Boulder, CO); Douglas G. Metcalf (Boulder, CO)
Assignee: Natural Extraction Systems, LLC
A23L2/38A23L2/395A61K9/0095A61K31/658
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,349,706
App. No.
17/392,247
Granted
Jul 8, 2025
Kind
B2
Abstract

Various aspects of this patent document relate to beverage concentrates that comprise active ingredients, containers comprising beverage concentrates, and methods to prepare beverage formulations from beverage concentrates.

Claims (43)

1. A method to prepare a beverage formulation, comprising:

providing a composition comprising an active ingredient;

providing a beverage; and

combining the composition with the beverage to disperse the active ingredient in the beverage and to prepare the beverage formulation,

wherein:

the composition comprises a solid phase and a liquid phase;

the solid phase has a surface-area-to-volume ratio that is greater than 500 per meter;

the solid phase consists of ingredients;

the ingredients of the solid phase comprise carbohydrates;

at least 90 percent of the ingredients of the solid phase consist of the carbohydrates by mass;

the composition comprises the liquid phase at a concentration of at least 0.5 percent and no greater than 15 percent by mass;

the composition comprises the solid phase at a concentration of at least 85 percent and no greater than 99.5 percent by mass;

the composition comprises at least 0.5 and no greater than 5 calories of food energy per gram of the composition;

the liquid phase comprises a concentration of calories of food energy per gram of the liquid phase;

the solid phase comprises a concentration of calories of food energy per gram of the solid phase that is less than the concentration of calories of food energy per gram of the liquid phase;

the liquid phase consists of ingredients that comprise a solvent;

each of the ingredients of the liquid phase has a concentration by mass in the liquid phase;

the concentration by mass of the solvent in the liquid phase is greater than the concentration by mass of any of the other ingredients of the liquid phase;

the solvent is propane-1,2-diol;

the ingredients of the liquid phase comprise the active ingredient;

the active ingredient is a solute that is dissolved in the solvent of the liquid phase;

the active ingredient is dissolved in the solvent of the liquid phase at a concentration of at least 200 micromolar and no greater than 250 millimolar;

the active ingredient has a solubility in water at 37 degrees Celsius;

the active ingredient is dissolved in the solvent of the liquid phase at a concentration that is greater than the solubility of the active ingredient in water at 37 degrees Celsius;

the active ingredient has an octanol-water partition coefficient of at least 10; and

the beverage is a liquid that comprises water at a concentration of at least 50 molar.

2. The method of claim 1 , comprising recording video or images of the composition both prior to and subsequent to combining the composition with the beverage.

3. The method of claim 1 , comprising combining at least 100 milligrams and no greater than 5 grams of the composition with the beverage.

4. The method of claim 1 , wherein the composition comprises at least 10 micrograms and no greater than 100 milligrams of the active ingredient.

5. The method of claim 1 , wherein the active ingredient is cannabidiol (CBD).

6. The method of claim 1 , wherein the active ingredient is tetrahydrocannabinol (THC).

7. The method of claim 1 , wherein the active ingredient is delta8-tetrahydrocannabinol (Δ8-THC).

8. The method of claim 1 , wherein the active ingredient is cannabigerol (CBG).

9. The method of claim 1 , wherein the active ingredient is cannabidivarin (CBDV).

10. The method of claim 1 , wherein the active ingredient is tetrahydrocannabivarin (THCV).

11. The method of claim 1 , wherein the active ingredient is delta8-tetrahydrocannabivarin (Δ8-THC).

12. The method of claim 1 , wherein the active ingredient is cannabigerovarin (CBGV).

13. The method of claim 1 , wherein the active ingredient is cannabinol (CBN).

14. The method of claim 1 , wherein the active ingredient is tetrahydrocannabiphorol.

15. The method of claim 1 , wherein the active ingredient is perrottetinene.

16. The method of claim 1 , wherein the active ingredient is nabilone.

17. The method of claim 1 , wherein the active ingredient is parahexyl.

18. The method of claim 1 , wherein the active ingredient is HU-331.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2025
From: THOMAS, C. RUSSELL; METCALF, DOUGLAS G.
To: NATURAL EXTRACTION SYSTEMS, LLC
Reel/Frame 071183/0054 →
Continuity (16)
Provisional Application 63228594 · Aug 2, 2021
Provisional Application 63228572 · Aug 2, 2021
Provisional Application 63228563 · Aug 2, 2021
Provisional Application 63194810 · May 28, 2021
Provisional Application 63191844 · May 21, 2021
Provisional Application 63191872 · May 21, 2021
Provisional Application 63191814 · May 21, 2021
Provisional Application 63191830 · May 21, 2021
Provisional Application 63154480 · Feb 26, 2021
Provisional Application 63154538 · Feb 26, 2021
Provisional Application 63154579 · Feb 26, 2021
Provisional Application 63154507 · Feb 26, 2021
Provisional Application 63148047 · Feb 10, 2021
Provisional Application 63130560 · Dec 24, 2020
Provisional Application 63059829 · Jul 31, 2020
Related Publication 20210360947A1 · Nov 25, 2021
References Cited (53)
US 6747058B1 · Dedhiya et al. · 2004 [cited by applicant]
US 8962696B2 · Harris et al. · 2015 [cited by applicant]
US 9907823B1 · Kuhrts · 2018 [cited by applicant]
US 10239848B2 · Gallily et al. · 2019 [cited by applicant]
US 10555914B1 · Metcalf · 2020 [cited by applicant]
US 10609944B1 · Metcalf · 2020 [cited by applicant]
US 10959961B2 · Metcalf · 2021 [cited by applicant]
US 20070105086A1 · Qin · 2007 [cited by applicant]
US 20080112895A1 · Kottayil · 2008 [cited by applicant]
US 20090044700A1 · Dietlin · 2009 [cited by applicant]
US 20140023614A1 · Barawkar et al. · 2014 [cited by applicant]
US 20140263467A1 · Wardle · 2014 [cited by applicant]
US 20150320720A1 · McAllister et al. · 2015 [cited by applicant]
US 20160018424A1 · Lucas et al. · 2016 [cited by applicant]
US 20170246897A1 · Brehm et al. · 2017 [cited by applicant]
US 20180049994A1 · Aung-Ding · 2018 [cited by applicant]
US 20180169035A1 · Eyal · 2018 [cited by applicant]
US 20180353463A1 · Winnicki · 2018 [cited by applicant]
US 20190030170A1 · Kingsley et al. · 2019 [cited by applicant]
US 20200245666A1 · Spall · 2020 [cited by examiner]
CA 2760460A1 · 2010 [cited by applicant]
CN 108314608A · 2018 [cited by applicant]
EP 1361864B1 · 2013 [cited by applicant]
EP 3061450A1 · 2016 [cited by applicant]
EP 3351242A1 · 2018 [cited by applicant]
EP 3459536A1 · 2019 [cited by applicant]
TW 201718493A · 2017 [cited by applicant]
WO 2006130679A2 · 2006 [cited by applicant]
WO 2006133941A2 · 2006 [cited by applicant]
WO 2011104667A1 · 2011 [cited by applicant]
WO 2013045115A1 · 2013 [cited by applicant]
WO 2015052568A2 · 2015 [cited by applicant]
WO 2017202424A1 · 2017 [cited by applicant]
WO 2018158150A1 · 2018 [cited by applicant]
WO 2018150182A1 · 2018 [cited by applicant]
WO 2018183115A1 · 2018 [cited by applicant]
WO 2019036243A1 · 2019 [cited by applicant]
WO 2020123809A1 · 2020 [cited by applicant]
WO 2020123976A1 · 2020 [cited by applicant]
WO 2020264199A1 · 2020 [cited by applicant]
WO 2021214762A1 · 2021 [cited by applicant]
Alejseev et al., “Technology of raising the availability of biologic and pharmaceutical drugs,” 2012, XIX(4):43-47. [cited by applicant]
Dow Corning, “Corning® Plastic Storage Bottles Selection Guide,” 2016, 8 pages. [cited by applicant]
Gelderblom et al., “Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation,” European Journal of Cancer, 2001, pp. 1590-1998, vol. 37. [cited by applicant]
Kogan et al., “Synthesis and antitumor activity of quinonoid derivatives of cannabinoids,” Journal of Medicinal Chemistry, 2004, pp. 3800-3806, vol. 47, issue 15. [cited by applicant]
Layton et al., “Forced degradation of cannabidiol,” 2016, publisher Waters Corporation, 6 pages. [cited by applicant]
Martijn, “CBD products according to sensi seeds,” 2016, 12 pages. [cited by applicant]
Mazina et al., “A rapid capillary electrophoresis method with LED-induced native fluorescence detection for the analysis of cannabinoids in oral fluid,” Analytical Methods, 2015, pp. 7741-7747, vol. 7. [cited by applicant]
Mechoulam et al., “Hashish-X111: On the nature of the beam test,” Tetrahedron, 1968, pp. 5615-5624, vol. 24, issue 16. [cited by applicant]
Mechoulam et al., “Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects,” Chemistry and Physics of Lipids, 2002, pp. 35-43, vol. 121. [cited by applicant]
Srebnik et al., “Base-catalysed double-bond isomerizations of cannabinoids: structural and stereochemical aspects,” Journal of the Chemical Society, Perkin Transactions I, 1984, pp. 2881-2886. [cited by applicant]
Starks, “Marijuana Chemistry: Genetics, Processing & Potency”, 2nd ed., 1990, onin Publishing, Inc. (Berkeley CA). [cited by applicant]
Wilson et al., “HU-331 and oxidized cannabidiol acts as inhibitors of human topoisomerase llα and β,” Chemical Research in Toxicology, 2017, pp. 137-144, vol. 31. [cited by applicant]